X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AMAR REMEDIES with Hindustan Unilever - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs HIND. UNILEVER - Comparison Results

HIND. UNILEVER 
   Change

HUL, the largest FMCG company in the country constitutes 13% of the industry valued at Rs. 1.6 trillion (AC Nielsen). It is present in over 20 distinct categories in Home & Personal Care Products and Foods & Beverages. Revenue share of the various pr... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES HIND. UNILEVER AMAR REMEDIES/
HIND. UNILEVER
 
P/E (TTM) x -0.5 64.0 - View Chart
P/BV x 0.1 48.2 0.1% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 AMAR REMEDIES   HIND. UNILEVER
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
HIND. UNILEVER
Mar-18
AMAR REMEDIES/
HIND. UNILEVER
5-Yr Chart
Click to enlarge
High Rs1641,415 11.6%   
Low Rs86899 9.6%   
Sales per share (Unadj.) Rs261.6164.2 159.3%  
Earnings per share (Unadj.) Rs17.424.1 72.1%  
Cash flow per share (Unadj.) Rs22.326.5 84.0%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs100.733.6 299.4%  
Shares outstanding (eoy) m26.162,164.53 1.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.57.0 6.8%   
Avg P/E ratio x7.247.9 15.0%  
P/CF ratio (eoy) x5.643.6 12.9%  
Price / Book Value ratio x1.234.4 3.6%  
Dividend payout %082.9 0.0%   
Avg Mkt Cap Rs m3,2702,504,686 0.1%   
No. of employees `000NA5.7 0.0%   
Total wages/salary Rs m16318,600 0.9%   
Avg. sales/employee Rs ThNM62,087.3-  
Avg. wages/employee Rs ThNM3,248.9-  
Avg. net profit/employee Rs ThNM9,126.6-  
INCOME DATA
Net Sales Rs m6,844355,450 1.9%  
Other income Rs m213,840 0.5%   
Total revenues Rs m6,865359,290 1.9%   
Gross profit Rs m1,13174,990 1.5%  
Depreciation Rs m1285,200 2.5%   
Interest Rs m398260 153.1%   
Profit before tax Rs m62673,370 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-330 15.2%   
Tax Rs m12120,790 0.6%   
Profit after tax Rs m45552,250 0.9%  
Gross profit margin %16.521.1 78.3%  
Effective tax rate %19.328.3 68.2%   
Net profit margin %6.614.7 45.2%  
BALANCE SHEET DATA
Current assets Rs m4,904116,600 4.2%   
Current liabilities Rs m3,58188,870 4.0%   
Net working cap to sales %19.37.8 247.8%  
Current ratio x1.41.3 104.4%  
Inventory Days Days12426 481.5%  
Debtors Days Days10013 744.5%  
Net fixed assets Rs m1,68949,890 3.4%   
Share capital Rs m2622,160 12.1%   
"Free" reserves Rs m2,35870,650 3.3%   
Net worth Rs m2,63572,810 3.6%   
Long term debt Rs m5070-   
Total assets Rs m6,862178,620 3.8%  
Interest coverage x2.6283.2 0.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.02.0 50.1%   
Return on assets %12.429.4 42.3%  
Return on equity %17.371.8 24.1%  
Return on capital %31.0100.7 30.8%  
Exports to sales %4.00-   
Imports to sales %00-   
Exports (fob) Rs m273NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2733,870 7.1%   
Fx outflow Rs m212,850 0.0%   
Net fx Rs m271-8,980 -3.0%   
CASH FLOW
From Operations Rs m-31360,640 -0.5%  
From Investments Rs m-489-10,680 4.6%  
From Financial Activity Rs m769-49,750 -1.5%  
Net Cashflow Rs m-33210 -15.5%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 67.3 -  
Indian inst/Mut Fund % 9.2 4.1 224.4%  
FIIs % 0.0 14.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 14.5 450.3%  
Shareholders   13,061 322,351 4.1%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   ARCHIES LTD  MARICO LTD  K.S.OILS LTD  LINC PEN & PLASTICS LTD  GILLETTE INDIA  

Compare AMAR REMEDIES With:   UNILEVER PLC. (UK)  P&G (US)  HYPERMARCAS (Brazil)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

HIND. UNILEVER 2017-18 Annual Report Analysis (Annual Result Update)

Aug 9, 2018 | Updated on Aug 9, 2018

Here's an analysis of the annual report of HIND. UNILEVER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of HIND. UNILEVER. Also includes updates on the valuation of HIND. UNILEVER.

HIND. UNILEVER Announces Quarterly Results (1QFY19); Net Profit Up 18.0% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, HIND. UNILEVER has posted a net profit of Rs 15 bn (up 18.0% YoY). Sales on the other hand came in at Rs 95 bn (up 2.9% YoY). Read on for a complete analysis of HIND. UNILEVER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS